ImmPACT Bio

Thrilled to announce that Lyell Immunopharma entered into a definitive agreement to acquire ImmPACT Bio! The combination will bring together a world-class Team and a pipeline of next-generation CAR T-cell therapies. Our first clinical data readout from IMPT-314’s ongoing Phase 1/2 study will be presented at a major medical conference later this year. “I am incredibly proud of the ImmPACT team and all of their accomplishments in developing next-generation CAR T-cell therapies,” stated Sumant Ramachandra, M.D., Ph.D., Chief Executive Officer of ImmPACT. “This transaction validates our novel science and enhances the potential for this therapy to make a meaningful impact on patients' lives. I am confident that in Lyell, we have found a team that shares our passion for advancing novel science to benefit patients.” Thank you to our employees, leadership team, collaborators, scientific and clinical partners, Founders, investors, Board of Directors, and many more people for the support as we built ImmPACT Bio from its academic roots to a company with several open INDs, ongoing clinical programs and a robust pipeline of next-generation CAR T-cell therapies. Read more here: https://lnkd.in/gy2dT-ta #CARTCellTherapy #NextGenerationTherapies #Biotechnology #MakeAnImmPACT

Welcome to the ImmPACT Bio team, Jesus Salas! #welcometotheteam, #cartcelltherapy, #MakeAnImmPACT

We stand with the fighters, celebrate the survivors, and honor the memory of those we've lost to this disease. Together, we raise awareness and push forward in the fight against breast cancer. Early detection and continued innovation in treatments make all the difference. Let’s keep working towards a future where breast cancer is a thing of the past. #BreastCancerAwareness #TogetherWeFight #ImmPACTBio

Welcome to the ImmPACT Bio team, Jenny Gong! #welcometotheteam, #CARTcelltherapy, #MakeAnImmPACT

ImmPACT Bio is pleased to announce that we will participate at the 2024 Cell and Gene Meeting on the Mesa, to be held October 7-9, 2024 in Phoenix, AZ. #cartcelltherapy, #CGMesa24, #MakeAnImmPACT

On this September 11, we pause to honor the memory of those we lost and express our gratitude to the heroes who emerged in the face of unimaginable tragedy. It's a reminder of the resilience, unity, and compassion that can arise in the darkest of times. #NeverForget #September11 #Resilience

Welcome to the ImmPACT Bio team, Marcia Friedman, M.D.! #welcometotheteam, #cartcelltherapy, #MakeAnImmPACT

ImmPACT Bio is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted IND clearance for IMPT-514, a bispecific CAR T therapy, as a potential treatment of adult patients with #multiplesclerosis (MS). This dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and the potential to reset the immune system. Read the press release: https://bit.ly/3YRCr1q #CARTcelltherapy, #celltherapy, #autoimmunedisease

Welcome to the ImmPACT Bio team, Amanda Squires! #Welcometotheteam, #CARTcelltherapy, #MakeAnImmPACT

Happy 4th of July! Today, we celebrate the values that make our nation strong: freedom, independence, and unity.